Aim Immunotech Stock News

OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update.

AIM ImmunoTech Inc (NYSE:AIM) closed its third quarter with a $53.7 million balance sheet as the company advances Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer.

AIM ImmunoTech (NYSE: AIM) is one of 232 publicly-traded companies in the Biological products, except diagnostic industry, but how does it contrast to its competitors? We will compare AIM ImmunoTech to related companies based on the strength of its dividends, risk, analyst recommendations, institutional ownership, valuation, earnings and profitability. Insider & Institutional Ownership 15.1% of []

AIM ImmunoTech Inc said it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the US Food and Drug Administration (FDA) for a planne

OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying applicat

AIM ImmunoTech Inc (NYSE:AIM) reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus (COVID-19) had shown "no severe adverse events" and that the drug was "gener

OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company's belief that its d

AIM ImmunoTech Inc announced that it has finalized the protocol for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. The company expec

Finalizes and reports Phase 2 study protocol

Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of

AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis against respiratory viruses. The HCT

AIM ImmunoTech Inc. said it has signed a signed clinical trial agreement for a Phase 2a Human Challenge Trial (HCT) with hVIVO for a Phase 2a Human Challenge Trial (HCT) to test the company's flagship

The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafter The governin

AIM ImmunoTech Inc (NYSE: AIM) submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen. The application is for two separate Phase 2 clinical studie

AIM ImmunoTech Inc announced it had submitted a pre-investigational New Drug application (pre-IND) to the US Food and Drug Administration (FDA) for two separate Phase 2 clinical studies to study Ampli